Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients

2017; SAGE Publishing; Volume: 26; Issue: 5 Linguagem: Inglês

10.1177/0961203316676386

ISSN

1477-0962

Autores

Clarissa Carvalho de Miranda Valões, B. Molinari, Ana C. Pitta, Natali W.S. Gormezano, Sylvia Costa Lima Farhat, Kátia Tomie Kozu, Adriana Maluf Elias Sallum, Simone Appenzeller, Ana Paula Sakamoto, Maria Teresa Terreri, Rosa Maria Rodrigues Pereira, Cláudia Saad Magalhães, Juliana Caires de Oliveira Achili Ferreira, Cássia Maria Passarelli Lupoli Barbosa, FH Gomes, Eloísa Bonfá, Clóvis A. Silva,

Tópico(s)

Immune Cell Function and Interaction

Resumo

Objectives Anti-ribosomal P protein (anti-P) autoantibodies are highly specific for systemic lupus erythematosus (SLE). However, the evaluation of this autoantibody in childhood-onset SLE (cSLE) populations has been limited to a few small series, hampering the interpretation of the clinical and laboratorial associations. Therefore, the objective of this multicenter cohort study was to evaluate demographic, clinical/laboratorial features, and disease damage score in cSLE patients with and without the presence of anti-P antibody. Methods This was a retrospective multicenter study performed in 10 pediatric rheumatology services of São Paulo state, Brazil. Anti-P antibodies were measured by ELISA in 228 cSLE patients. Results Anti-P antibodies were observed in 61/228 (27%) cSLE patients. Frequencies of cumulative lymphadenopathy (29% vs. 15%, p = 0.014), acute confusional state (13% vs. 5%, p = 0.041), mood disorder (18% vs. 8%, p = 0.041), autoimmune hemolytic anemia (34% vs. 15%, p = 0.001), as well as presence of anti-Sm (67% vs. 40%, p = 0.001), anti-RNP (39% vs. 21%, p = 0.012) and anti-Ro/SSA antibodies (43% vs. 25%, p = 0.016) were significantly higher in cSLE patients with anti-P antibodies compared to those without these autoantibodies. A multiple regression model revealed that anti-P antibodies were associated with autoimmune hemolytic anemia (odds ratio (OR) = 2.758, 95% confidence interval (CI): 1.304–5.833, p = 0.008) and anti-Sm antibody (OR = 2.719, 95% CI: 1.365–5.418, p = 0.004). The SLICC/ACR damage index was comparable in patients with and without anti-P antibodies ( p = 0.780). Conclusions The novel association of anti-P antibodies and autoimmune hemolytic anemia was evidenced in cSLE patients and further studies are necessary to determine if anti-P titers may vary with this hematological manifestation.

Referência(s)